These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14998859)

  • 21. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.
    Gabizon A; Peretz T; Sulkes A; Amselem S; Ben-Yosef R; Ben-Baruch N; Catane R; Biran S; Barenholz Y
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1795-803. PubMed ID: 2632261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
    Conley BA; Egorin MJ; Whitacre MY; Carter DC; Zuhowski EG; Van Echo DA
    Cancer Chemother Pharmacol; 1993; 33(2):107-12. PubMed ID: 8261569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
    Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
    Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
    J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors.
    Hauck ML; LaRue SM; Petros WP; Poulson JM; Yu D; Spasojevic I; Pruitt AF; Klein A; Case B; Thrall DE; Needham D; Dewhirst MW
    Clin Cancer Res; 2006 Jul; 12(13):4004-10. PubMed ID: 16818699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.
    Nagata N; Kobayashi M; Kojima H; Kondo K; Hirabayashi N; Matsui T; Kataoka M; Takiyama W; Miyashita Y; Nakazato H; Araki K; Itoh H; Nakao A; Sakamoto J
    Hepatogastroenterology; 2005; 52(66):1905-10. PubMed ID: 16334804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia.
    Unezaki S; Maruyama K; Takahashi N; Koyama M; Yuda T; Suginaka A; Iwatsuru M
    Pharm Res; 1994 Aug; 11(8):1180-5. PubMed ID: 7971721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
    Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
    Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).
    Bjarnason GA; Charpentier D; Wong R; Goel R; Douglas L; Walsh W; Matthews S; Dent S; Seymour L; Winquist E
    Invest New Drugs; 2005 Jan; 23(1):51-6. PubMed ID: 15528980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
    Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
    J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.